Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.

American journal of respiratory and critical care medicine·2026
Same author

Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries.

The Lancet. Respiratory medicine·2026
Same author

Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study.

The Lancet. Respiratory medicine·2026
Same author

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Design and rationale of the AIR-NET trial: a randomised, open-label, multifactorial, multicentre, adaptive platform trial using a range of repurposed anti-inflammatory treatments to improve outcomes in patients with bronchiectasis within the EMBARC clinical research network.

ERJ open research·2026

Related Experiment Video

Updated: May 6, 2026

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model
07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

3.3K

Developing an international Pseudomonas aeruginosa reference panel.

Anthony De Soyza1, Amanda J Hall, Eshwar Mahenthiralingam

  • 1Institute of Cellular Medicine, Newcastle University, Newcastle, U.K.

Microbiologyopen
|November 12, 2013
PubMed
Summary
This summary is machine-generated.

This study introduces a diverse Pseudomonas aeruginosa reference panel to aid research. This resource will advance understanding of virulence and antimicrobial resistance in cystic fibrosis patients and other populations.

Keywords:
Cystic fibrosisPseudomonas aeruginosagenotypepathogen

More Related Videos

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
11:35

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants

Published on: May 4, 2018

7.6K
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

34.5K

Related Experiment Videos

Last Updated: May 6, 2026

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model
07:39

Tools for the Real-Time Assessment of a Pseudomonas aeruginosa Infection Model

Published on: April 6, 2021

3.3K
Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
11:35

Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants

Published on: May 4, 2018

7.6K
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

34.5K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Genomics

Background:

  • Pseudomonas aeruginosa is a significant opportunistic pathogen, particularly in cystic fibrosis (CF) patients, known for its antimicrobial resistance and diverse strains.
  • Current research often overlooks the full diversity of P. aeruginosa, focusing on a limited number of strains, which hinders a comprehensive understanding of its virulence and pathogenesis.

Purpose of the Study:

  • To establish a standardized reference panel of Pseudomonas aeruginosa strains that accurately reflects the species' diversity.
  • To provide a consolidated resource for the research community to accelerate the discovery of virulence factors and improve understanding of P. aeruginosa infections.

Main Methods:

  • A curated panel of 43 P. aeruginosa strains was assembled.
  • The panel includes commonly studied clones, transmissible strains, sequential isolates from CF patients, and strains representing diverse serotypes, genotypes, and geographic origins.

Main Results:

  • The developed panel encompasses a broad spectrum of P. aeruginosa diversity, including clinical and environmental isolates.
  • This resource facilitates comparative studies on virulence, pathogenesis, and antimicrobial resistance across different P. aeruginosa populations.

Conclusions:

  • The P. aeruginosa reference panel serves as a valuable community resource for advancing research into virulence determinants and pathogenesis.
  • This standardized collection of isolates will aid in the development and testing of novel therapeutic agents against P. aeruginosa infections.